Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INJECTAPAP vs ACHROMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Management of mild to moderate pain,Reduction of fever
Infections caused by susceptible strains of bacteria (e.g., Mycoplasma pneumoniae, Chlamydia trachomatis, Rickettsia species),Acne vulgaris,Periodontitis (as adjunctive therapy),Off-label: Chronic obstructive pulmonary disease exacerbations, malaria prophylaxis
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily renally excreted unchanged; minimal hepatic metabolism.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
10-25% bound to albumin at therapeutic concentrations.
50-60% bound to serum proteins
0.8-1.0 L/kg; suggests distribution into total body water.
1.5-2.0 L/kg; indicates extensive tissue penetration
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
Oral: 75-80%; Topical: minimal systemic absorption
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12-24 hours; GFR <10 m L/min: administer every 24 hours or avoid.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
25-50 mg/kg/day orally divided every 6 hours; maximum 2 g/day.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Initiate at lower end of dosing range due to age-related renal function decline; monitor renal function.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
No FDA boxed warning
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Photosensitivity reactions,Esophageal ulceration if taken with insufficient fluids,Pseudotumor cerebri in adults,Pancreatitis,Hepatotoxicity,Renal impairment (accumulation may worsen renal function),Superinfection with resistant organisms
Hypersensitivity to acetaminophen or any component of the formulation
Hypersensitivity to tetracyclines,Pregnancy (second and third trimesters) due to fetal harm,Children under 8 years due to permanent tooth discoloration and enamel hypoplasia,Severe hepatic or renal impairment
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Avoid dairy products (milk, cheese, yogurt) within 2-3 hours of taking Achromycin, as calcium binds tetracycline and reduces absorption. Also avoid iron-fortified foods, calcium-fortified juices, and high-calcium meals. Take on an empty stomach with a full glass of water; food, especially dairy, decreases absorption by up to 50%.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure can cause permanent discoloration of deciduous teeth (yellow-gray-brown) due to deposition during calcification, and reversible inhibition of bone growth. Avoid use after the fourth month of pregnancy. Risk of maternal hepatotoxicity if used intravenously in pregnancy.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Tetracycline is excreted into breast milk in low concentrations. Theoretical risk of dental discoloration and bone growth suppression in nursing infants, but levels are usually below therapeutic. M/P ratio is approximately 0.5-0.8. Use with caution, especially in infants with prolonged exposure. American Academy of Pediatrics considers tetracyclines compatible with breastfeeding.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
No dosage adjustment is recommended for pregnancy; however, use is contraindicated after the first trimester due to risks to the fetus. If essential, use the lowest effective dose for the shortest duration. Intravenous doses should be cautious due to risk of hepatotoxicity; reduce dose in renal impairment.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Achromycin (tetracycline) should be administered on an empty stomach (1 hour before or 2 hours after meals) to ensure adequate absorption. Avoid concurrent use with dairy products, antacids, iron, calcium, magnesium, or bismuth subsalicylate as they chelate tetracycline and reduce absorption. Tetracycline can cause photosensitivity; advise patients to avoid prolonged sun exposure and use sunscreen. It is contraindicated in pregnancy (risk of hepatotoxicity and fetal bone/teeth discoloration), lactation, and children under 8 years (permanent tooth discoloration and bone growth inhibition). Monitor for signs of superinfection, especially Clostridium difficile-associated diarrhea. Tetracycline may increase the effect of warfarin; monitor INR closely.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not take with dairy products, antacids, iron supplements, or calcium supplements; separate by at least 2-3 hours.,Avoid excessive sunlight or tanning beds; use sunscreen and wear protective clothing to prevent severe sunburn.,Complete the full course of treatment even if you feel better; do not skip doses.,Notify your doctor immediately if you develop watery or bloody diarrhea, rash, headache, blurred vision, or signs of infection worsening.,Do not use if you are pregnant, planning to become pregnant, or breastfeeding; this medication can harm the unborn baby or nursing infant.,Keep out of reach of children; expired tetracycline can cause kidney damage.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INJECTAPAP vs ACHROMYCIN, answered by our medical review team.
INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. ACHROMYCIN is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INJECTAPAP and ACHROMYCIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of ACHROMYCIN is: 250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INJECTAPAP and ACHROMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. ACHROMYCIN is classified as Category C. ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure ca. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.